Advancing Therapeutics, Improving Lives

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet need. With each new discovery and experimental drug candidate, we seek to improve the care of patients suffering from life-threatening diseases.

Gilead’s primary areas of focus include: antivirals (such as HIV/AIDS and chronic hepatitis), cardiovascular conditions (such as pulmonary arterial hypertension and resistant hypertension) and respiratory diseases (such as influenza and cystic fibrosis).

Our portfolio of 11 marketed products includes a number of category firsts and market leaders, including Atripla® - the first single tablet regimen for HIV infection. Gilead scientists invented the anti-influenza drug Tamiflu® (oseltamivir), which is marketed globally by Hoffmann-La Roche. The company's latest therapy, Letairis® (ambrisentan), was approved in June 2007 and is a once-daily oral treatment for pulmonary arterial hypertension (PAH). PAH is a progressive, life-threatening disease for which new therapies are urgently needed.

20 Years of Growth

Gilead was founded in 1987 in Foster City, California. John C. Martin, PhD has been the company's President and Chief Executive Officer since 1996. In just 20 years, Gilead has become one of the largest biopharmaceutical companies in the world, with a rapidly expanding product portfolio, growing pipeline of investigational drugs, more than 3,000 employees and operations on three continents.

In 2007, Gilead annual revenues surpassed $4 billion. BusinessWeek magazine ranked Gilead third in its 2007 list of the Top 50 best-performing companies.

Our Marketed Products

Following is a summary of Gilead's product portfolio. See our Products section for full prescribing information, including BOXED WARNINGS and important safety information.

Antiviral

• Atripla® (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg) is the first and only once-daily single tablet regimen for the treatment of HIV infection in adults. It is intended for use as a stand-alone therapy, or in combination with other antiretrovirals, and combines Gilead's Truvada® (emtricitabine and tenofovir disoproxil fumarate) with Sustiva® (efavirenz), manufactured by Bristol-Myers Squibb. (U.S. approval, 2006.)
• Truvada® (emtricitabine and tenofovir disoproxil fumarate) is a fixed-dose once-daily combination pill containing Viread® and Emtriva®. It is used in combination with other antiretroviral agents for the treatment of HIV infection in adults. (U.S. approval, 2004; E.U. approval, 2005.)
• Viread® (tenofovir disoproxil fumarate) is a once-daily oral nucleotide reverse transcriptase inhibitor (NtRTI) for the treatment of HIV infection in adults in combination with other antiretroviral agents. (U.S. approval, 2001; E.U. approval, 2002.)
• Emtriva® (emtricitabine) is a once-daily oral nucleoside reverse transcriptase inhibitor (NRTI) used in combination with other antiretroviral agents for the treatment of HIV infection in adults. Emtriva is also available as an oral solution for use in pediatric patients. (U.S. and E.U. approval, 2003.)
• Hepsera® (adefovir dipivoxil) is a once-daily, oral NtRTI for the treatment of patients with chronic hepatitis B. (U.S. approval, 2002; E.U. approval, 2003.)

Cardiovascular

• Letairis® (ambrisentan) is a novel endothelin receptor antagonist indicated for the once-daily treatment of pulmonary arterial hypertension (WHO Group 1) in patients with WHO Functional Class II or III symptoms to improve exercise capacity and delay clinical worsening. (U.S. approval 2007; GlaxoSmithKline holds rights to commercialize the product outside of the United States.)
• Flolan® (epoprostenol sodium for injection) is a long-term intravenous treatment for primary pulmonary hypertension and certain other forms of the disease. Flolan was developed by GlaxoSmithKline; Gilead commercializes the product in the United States. (U.S. approval, 1995.)

Respiratory

• Tamiflu® (oseltamivir phosphate) is the first neuraminidase inhibitor tablet for the treatment and prevention of influenza A and B. Tamiflu was approved by the FDA for the treatment of influenza in October 1999 and for influenza prevention in November 2000. Tamiflu has been available in Europe since 2002. The product, which was developed by Gilead, is commercialized globally by Hoffmann-La Roche.

Other

• AmBisome® (amphotericin B liposome for injection) is a treatment for life-threatening, systemic fungal infections in adults. (E.U. approval, 1990; U.S. approval, 1997.)
• Macugen® (pegaptanib sodium injection) is an injection for the treatment of neovascular age-related macular degeneration (also known as "wet" AMD), an eye disease that destroys central vision in elderly patients. This product is marketed in the United States by OSI Pharmaceuticals. (U.S. approval, 2004.)
• Vistide® (cidofovir injection) is an antiviral injection for the treatment of cytomegalovirus retinitis in adult patients with AIDS. (U.S. approval, 1996; E.U. approval, 1997.)

Science & Research

Gilead's research and development program identifies and evaluates compounds that show potential to advance the treatment of life-threatening diseases in areas of unmet medical need.

Gilead currently has several drugs in development in its target therapeutic areas. Please visit the Science & Research section for more information about the company's R&D activities.

Phase III

• Viread is currently being evaluated as a potential treatment for chronic hepatitis B infection.
• Aztreonam lysine for inhalation is an antibiotic for patients with cystic fibrosis (CF). Currently in Phase III clinical trials, the compound targets Gram-negative bacteria that are the principal cause of death for individuals with CF.
• Darusentan is an endothelin receptor antagonist for the treatment of resistant hypertension.
  Cystic Fibrosis
  Cystic fibrosis (CF) is a chronic, debilitating genetic disease. A major characteristic of CF is production of abnormally thick, sticky mucus in the lungs, trapping bacteria and continually predisposing patients to damaging lung infections. Currently there is no known cure for CF; the goal of therapy is to control symptoms and prevent further lung damage. Today, more than 30,000 people in the United States have CF.

Phase II

• Elvitegravir (GS 9137) is one of the first candidates in a new class of HIV drugs known as integrase inhibitors. Phase II data were presented in early 2007.
  HIV/AIDS
  More than 40 million people worldwide are infected with HIV, the virus that causes AIDS. New types of antiretroviral drugs are urgently needed by HIV patients who have become resistant to currently available medications. The development of drug resistance is the leading cause of HIV treatment failure.

Phase I

• GS 9190 is an investigational non-nucleoside polymerase inhibitor for hepatitis C infection (HCV). Gilead commenced clinical evaluation of GS 9190 in hepatitis C-infected individuals in late 2006.
• GS 9219 is an investigational nucleotide analogue that is being evaluated as a treatment for certain cancers. In 2006 Gilead submitted an investigational New Drug Application to the U.S. Food and Drug Administration (FDA), and GS 9219 will enter a Phase I human trial involving patients with non-Hodgkins lymphoma and chronic lymphocytic leukemia in late 2007.

Viread for the treatment of chronic hepatitis B, aztreonam lysine for inhalation, darusentan, elvitegravir (GS 9137), GS 9190 and GS 9219 are investigational treatments and have not yet been determined safe or efficacious in humans.

Growing Worldwide Footprint

Gilead has more than 3,000 employees around the world. Corporate headquarters are located in Foster City, California. We also have additional operations in:

United States

• Durham, North Carolina
• San Dimas, California
• Seattle, Washington
• Westminster, Colorado

Canada

• Edmonton, Alberta
• Mississauga, Ontario

Europe

• Stockley Park, U.K. (International headquarters)
• Athens, Greece
• Cambridge, U. K.
• Cork and Dublin, Ireland
• Istanbul, Turkey
• Lisbon, Portugal
• Madrid, Spain
• Milan, Italy
• Munich, Germany
• Paris, France
• Stockholm, Sweden
• Vienna, Austria

Australia

• Melbourne, Victoria

Corporate Responsibility

As Gilead grows as a company, so do our responsibilities as a corporate citizen. We strive to play our part in expanding global access to our medications and to give back to the communities in which we operate.

Gilead recognizes the urgent need for access to HIV medications worldwide, particularly in developing countries where the AIDS epidemic is devastating communities. We believe that the medicines we develop should be accessible to all patients who need them worldwide, regardless of income or location. To date, more than 100,000 patients in the developing world have received Gilead's therapies for the treatment of HIV. We are undertaking the following initiatives to help further expand access to our medicines in resource-limited settings:

• Gilead Access Program
  Since early 2003, we have operated an access program to provide Viread and Truvada at substantially reduced prices in many low- and middle-income countries.
• Local Manufacturing in Africa
  In 2005, Gilead entered into a non-exclusive partnership with South Africa-based Aspen Pharmacare, under which Aspen manufactures finished product for access program countries and distributes Gilead therapies throughout Africa.
• Partnerships with Indian Generic Manufacturers
  Gilead has signed non-exclusive licenses with multiple generic manufacturers in India. Under these agreements, our partners will produce high-quality generic versions of Viread in 95 resource-limited countries, which are home to 95 percent of the world's HIV-infected people. We expect that multiple manufacturers will ensure competitive pricing, thus promoting broad access to our products for patients in developing countries with HIV/AIDS.
• A Commitment to Research and Development
  Gilead has an active research and development program aimed at identifying new compounds for the treatment of life-threatening diseases (see Science & Research section for more information).
• Ongoing Research Collaborations
  We are also working with academic, government and private sector partners to better understand the profile of our products in important areas such as pediatric HIV care, prevention of mother-to-child HIV transmission and pre-exposure prophylaxis.
• Patient Access in the United States
  Gilead supports a number of programs for eligible patients in the United States who do not have insurance, are underinsured or who otherwise need financial assistance. These programs include U.S. Advancing Access™, Atripla® Patient Access Program and Gilead™Solutions.
• The Gilead Foundation
  Established in 2005, the Foundation is a non-profit organization that seeks to enhance access to healthcare around the world. Since its inception, the Gilead Foundation distributed funds to more than 60 organizations to support HIV education, healthcare training and infrastructure and treatment programs in low-income countries. The Foundation also supports disease awareness and education programs in the United States.
• Support for Community Organizations/Events
  Gilead provides unrestricted grants to non-profit organizations across the United States that advocate for people with serious, life-threatening diseases. In addition, the company sponsors national and local awareness-raising and fund-raising events, such as National HIV Testing Day, local AIDS and Liver Walks and California's AIDS LifeCycle, to name just a few.

Please visit our Corporate Responsibility section for more information on Gilead's work in our communities.

Leadership

Following is a list of Gilead's Executive Committee. See the Leadership section for bios of these individuals as well as Gilead's Board of Directors and Scientific Advisory Board.

• John C. Martin, PhD, Chairman, Board of Directors and Chief Executive Officer
• John F. Milligan, PhD, President and Chief Operating Officer
• Norbert W. Bischofberger, PhD, Executive Vice President, Research and Development and Chief Scientific Officer
• Kevin Young, Executive Vice President, Commercial Operations
• Gregg H. Alton, Senior Vice President and General Counsel
• Anthony D. Caracciolo, Senior Vice President, Manufacturing and Operations
• Paul Carter, Senior Vice President, International Commercial Operations
• Richard J. Gorczynski, PhD, Senior Vice President, Cardiovascular Research
• William A. Lee, PhD, Senior Vice President, Research
• Kristen M. Metza, Senior Vice President, Human Resources
• James R. Meyers, Senior Vice President, Commercial Operations, North America
• A. Bruce Montgomery, MD, Senior Vice President, Head of Respiratory Therapeutics
• John J. Toole, MD, PhD, Senior Vice President, Corporate Development
• Robin L. Washington, Senior Vice President and Chief Financial Officer
• Taiyin Yang, PhD, Senior Vice President, Pharmaceutical Development and Manufacturing

More Information

For more information about Gilead, its products or community involvement, please contact Gilead Public Affairs at +1 (650) 574-3000 or submit a media inquiry online.